KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Net Income towards Common Stockholders (2016 - 2025)

Historic Net Income towards Common Stockholders for Halozyme Therapeutics (HALO) over the last 17 years, with Q3 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Net Income towards Common Stockholders rose 2789.12% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 5172.49%. This contributed to the annual value of $444.1 million for FY2024, which is 5770.61% up from last year.
  • According to the latest figures from Q3 2025, Halozyme Therapeutics' Net Income towards Common Stockholders is $175.2 million, which was up 2789.12% from $165.1 million recorded in Q2 2025.
  • Halozyme Therapeutics' Net Income towards Common Stockholders' 5-year high stood at $216.6 million during Q3 2021, with a 5-year trough of $22.7 million in Q2 2022.
  • Over the past 5 years, Halozyme Therapeutics' median Net Income towards Common Stockholders value was $81.8 million (recorded in 2023), while the average stood at $94.2 million.
  • As far as peak fluctuations go, Halozyme Therapeutics' Net Income towards Common Stockholders surged by 55707.03% in 2021, and later tumbled by 7519.63% in 2022.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Net Income towards Common Stockholders stood at $66.8 million in 2021, then fell by 13.58% to $57.7 million in 2022, then skyrocketed by 47.98% to $85.4 million in 2023, then skyrocketed by 60.46% to $137.0 million in 2024, then increased by 27.89% to $175.2 million in 2025.
  • Its Net Income towards Common Stockholders stands at $175.2 million for Q3 2025, versus $165.1 million for Q2 2025 and $118.1 million for Q1 2025.